Accelerating Biotechnology Patient Access in Europe Through Strategic Policy Reforms

The biotechnology patient access gap in Europe remains a critical challenge despite the continent’s scientific excellence. The EU Biotech Act offers a strategic opportunity to accelerate the delivery of advanced therapies — such as radioligand, cell and gene, and RNA-based treatments — from discovery to real-world patient benefit.

Europe continues to lead in biotechnology research, yet systemic barriers frequently block timely patient access, according to a recent EFPIA Guest Blog. Fragmented regulatory pathways, slow clinical trial approvals, and regulatory uncertainty drive investment and development away from the region. Without urgent reform, promising breakthroughs risk remaining out of reach for patients who need them most.

The High-Risk Reality of Next-Generation Biotechnologies

Advanced platforms like cell and gene therapies and radioligand therapies demand specialized infrastructure, multidisciplinary expertise, secure supply chains, and aligned oversight far beyond traditional drug development. Global investors prioritize speed and predictability. Europe’s inconsistent clinical trial processes and lack of a consistent, broad definition of biotechnology threaten to exclude emerging technologies from essential policy support.

Three Policy Pillars to Bridge Discovery and Delivery

The EU Biotech Act must deliver three interdependent foundations: meaningful extensions to Supplementary Protection Certificates for qualifying biotech and advanced therapies, a future-proof and technology-neutral definition of biotechnology, and comprehensive harmonization of clinical trial authorization. These reforms are not merely pro-innovation measures — they are essential mechanisms to shorten the lag between scientific breakthrough and biotechnology patient access.

Strategic Implications for Market Access and HEOR

For Health Economics and Outcomes Research (HEOR) and market access professionals, the Act’s success will reshape pricing, reimbursement, and evidence-generation strategies. Extended protection periods and faster development pathways can improve return-on-investment calculations for high-risk programs, while system-readiness requirements for complex therapies will demand integrated evidence plans addressing both clinical and organizational barriers.

By treating innovation and access as mutually reinforcing priorities rather than sequential steps, the EU Biotech Act can catalyze sustainable funding models, accelerate biotechnology patient access, and strengthen Europe’s global competitiveness in the life-sciences economy.

(Source: EFPIA guest blog on the EU Biotech Act)